← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 2000First marketed drug
Aug 19, 2011First NDA
Aug 19, 2011Last known activity
Apr 30, 2025
Acquired by Pfizer on Mar 13, 2023
Timeline
1990s
- Jan 1, 1997
Seattle Genetics— Founded
2010s
- Mar 9, 2018
Cascadian Therapeutics Inc.— Acquired
Drugs by trial phase (138 distinct, 212 trials)
Phase 4 (6 own, 0 via acquisition)
Phase 3 (31 own, 9 via acquisition)
Phase 2 (43 own, 4 via acquisition)
Phase 1 (40 own, 5 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Anemia, Refractory
- Anemia, Refractory, with Excess of Blasts
- Biliary Tract Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Burkitt Lymphoma
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Central Nervous System Diseases
- Cholangiocarcinoma
- Colorectal Neoplasms
- Disease
- Epstein-Barr Virus Infections
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Fallopian Tube Neoplasms
- Gastrointestinal Neoplasms
- Graft vs Host Disease
- Head and Neck Neoplasms
- Hematologic Diseases
- Hodgkin Disease
- Immunoblastic Lymphadenopathy
- Intraocular Lymphoma
- Leukemia
- Leukemia, Hairy Cell
- Leukemia, Large Granular Lymphocytic
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Leukemia, Promyelocytic, Acute
- Leukemia, T-Cell
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Lymphatic Diseases
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Lymphomatoid Granulomatosis
- Lymphomatoid Papulosis
- Lymphoproliferative Disorders
- Mesothelioma
- Multiple Myeloma
- Mycoses
- Mycosis Fungoides
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Squamous Cell
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Pelvic Neoplasms
- Plasmablastic Lymphoma
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Prostatic Neoplasms
- Sarcoma
- Sarcoma, Kaposi
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sclerosis
- Sezary Syndrome
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Syndrome
- Triple Negative Breast Neoplasms
- Ureteral Neoplasms
- Urethral Neoplasms
- Urinary Bladder Neoplasms
- Urologic Neoplasms
- Uterine Cervical Neoplasms
- Uterine Neoplasms
- Waldenstrom Macroglobulinemia
Marketed drugs (3)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT04220203Lead sponsorN/A—
- NCT06362590Lead sponsorN/A—
- NCT04136808CollaboratorN/A—
- NCT06809140CollaboratorPhase 2Apr 30, 2025
- NCT06549816OfficialPhase 1Aug 21, 2024
- NCT06549816Lead sponsorPhase 1Aug 21, 2024
- NCT06466187OfficialPhase 1Aug 2, 2024
- NCT06466187Lead sponsorPhase 1Aug 2, 2024
- NCT06254495Lead sponsorPhase 1May 28, 2024
- NCT06254495OfficialPhase 1May 28, 2024
- NCT06377566CollaboratorPhase 2Apr 17, 2024
- NCT06157892Lead sponsorPhase 1/Phase 2Feb 29, 2024
- NCT06157892Study directorPhase 1/Phase 2Feb 29, 2024
- NCT06120504Study directorPhase 1Jan 31, 2024
- NCT06120504Lead sponsorPhase 1Jan 31, 2024
Details
- Founded
- Bothell, WA, US Jan 1, 1997
- First NDA
- Aug 19, 2011
- Last known activity
- Apr 30, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval